NASA built a blood-clot risk score for astronauts far from a hospital

Microgravity changes the way blood moves through an astronaut’s body, creating risks that ordinary hospital scoring systems were not built to capture. NASA medical experts have developed a venous thromboembolism risk algorithm that combines neck-vein flow findings with other clotting factors. The tool is meant to support consistent decisions in an environment where imaging is limited and emergency care is far away.

Microgravity can slow or reverse blood flow in the neck

Venous thromboembolism, or VTE, includes deep-vein thrombosis and pulmonary embolism. Both involve clots forming in the venous system, with the possibility that a clot can travel and obstruct blood flow in the lungs. On Earth, immobility, surgery, cancer, hormones and inherited factors can change risk. Spaceflight adds fluid shifts and unusual flow patterns that do not map neatly onto terrestrial experience.

NASA’s updated account of the astronaut algorithm identifies stasis in the left internal jugular vein as a dominant concern in microgravity. Experts continue to debate the relative roles of slow flow, backward flow and changes at the vessel wall. That uncertainty makes a structured assessment useful, but it also means the score must remain connected to clinical judgment.

In-flight ultrasound does not answer every question

Ultrasound can visualize a neck vein and help crews assess blood movement, but equipment and operator conditions aboard a spacecraft differ from those in a vascular laboratory. Measuring slow flow precisely is difficult, and qualitative findings can be interpreted differently. Communication delays on distant missions could further complicate real-time consultation with specialists on Earth.

The working group recommended more study of in-flight stasis assessment instead of treating a single measurement as infallible. Members also considered retrograde flow and other thrombosis risk factors. A majority supported prophylaxis when stasis alone is present or when a weighted combination of other factors crosses the algorithm’s threshold. The recommendation describes NASA’s operational framework, not general medical advice for patients on Earth.

The score grew from real spaceflight case reviews

NASA first convened a VTE working group in October 2024 after thromboembolisms had been diagnosed during International Space Station missions. In April 2026, the Office of the Chief Health and Medical Officer initiated another review using updated case information and additional data showing altered blood flow within a cohort of astronauts.

Experts examined clinical practice, current research and mitigation options. They then developed the risk score from a literature review and the panel’s conclusions, weighting non-stasis factors with evidence from terrestrial medicine. This approach acknowledges that astronaut data remain limited while avoiding the opposite error of ignoring established knowledge about clot formation.

Medication decisions carry risks of their own

Anticoagulants can reduce the chance that a clot forms or grows, but they also raise bleeding risk. That tradeoff becomes more complicated in space, where trauma, emergency procedures and medication storage must be considered. Any prophylaxis plan needs clearly defined triggers, dosing protocols, contraindications and monitoring procedures.

NASA’s human-spaceflight standards program turns medical evidence into requirements and clinical guidance for missions. A risk algorithm provides a common decision path so similar findings do not produce inconsistent responses. It can also reveal where a mission lacks the imaging, laboratory capability or medication supply needed to carry out the plan.

Distance increases the value of a decision framework

Crews aboard the space station can communicate rapidly with ground teams and, under extraordinary circumstances, return to Earth. A mission to Mars would face long travel times and communication delays, eliminating any practical route to a terrestrial emergency department. Medical systems must therefore emphasize prevention, early recognition and autonomous care.

The agency’s research on the human body in space spans fluid shifts, bone and muscle loss, radiation, immune changes and other hazards. VTE risk sits within that wider system. Exercise schedules, vehicle design, mission duration and individual medical histories can interact, so the score is one tool within a larger health architecture rather than a substitute for it.

More flight data will determine how the score evolves

The small astronaut population limits statistical certainty. A scoring system built from expert review and terrestrial evidence must be tested against future observations, and its thresholds may change as ultrasound methods improve or more long-duration missions generate data. Privacy protections are especially important because the pool of possible individuals is so small.

Even with those limits, formalizing the reasoning is an important step. It converts scattered case experience into a repeatable process, identifies what crews need to measure and links findings to preplanned options. For missions far from immediate hospital care, that preparation can be as important as the medicine carried aboard.

The framework can also influence spacecraft design before launch. If a decision depends on a particular ultrasound view, vehicle planners must provide suitable equipment, crew training and communications support. If prophylaxis is a possible response, pharmacy supplies and bleeding-management plans must reflect that choice. A score therefore connects clinical evidence to hardware, training and mission logistics rather than functioning as an isolated checklist.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview